NASDAQ$BMRN
BioMarin Pharmaceutical Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
BioMarin's Q4 2021 financial results reflected a slight decrease in total revenues compared to the same period in 2020, but the company established the foundation for a return to double-digit revenue growth and profitability in 2022.
BioMarin Pharmaceutical Inc. announced its Q4 and full-year 2021 financial results, with total revenues for the fourth quarter of 2021 were $449.8 million, essentially flat compared to the same period in 2020. The company is focusing on the launch of Voxzogo and the potential approval of valoctocogene roxaparvovec to drive growth in 2022.
- Total Revenues for Q4 2021 were $449.8 million, essentially flat compared to Q4 2020.
- GAAP Net Loss increased to $57.9 million for Q4 2021, compared to GAAP Net Income of $22.1 million for Q4 2020.
- Non-GAAP Income for Q4 2021 decreased to $7.1 million, compared to $39.5 million for the same period in 2020.
- Full-year 2022 Total Revenue Guidance of $2.05 Billion to $2.15 Billion, Representing 14% Growth Year-Over-Year.
Headline financials
Revenue & EPS history
BioMarin · Revenue · Quarterly
$450M
Revenue by segment
BioMarin · $435M total across 7 segments · Q4 2021
- VIMIZIM$156M+9.7%35.9%
- NAGLAZYME$83.1M-30.6%19.1%
- KUVAN$68.5M-23.0%15.7%
- PALYNZIQ$63.8M+28.6%14.7%
- BRINEURA$37.4M+6.9%8.6%
- ALDURAZYME$20.3M+1591.7%4.7%
- VOXZOGO$5.8M—1.3%
Forward guidance
BioMarin provided full-year 2022 financial guidance, including total revenues between $2.05 billion and $2.15 billion and GAAP Net Income between $95 million and $135 million.
Tailwinds
- Total Revenues $2,050 to $2,150 million
- Vimizim Net Product Revenues $650 to $700 million
- Naglazyme Net Product Revenues $400 to $440 million
- Palynziq Net Product Revenues $280 to $310 million
- Brineura Net Product Revenues $145 to $160 million
Headwinds
- Kuvan Net Product Revenues $225 to $250 million
- Cost of Sales (% of Total Revenues) 23% to 25%
- Research and Development Expense $665 to $715 million
- Selling, General and Administrative Expense $790 to $840 million
- GAAP Net Income $95 to $135 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
-0.5%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-0.6%
Avg return
30 days after
44%
30 / 68 earnings
Positive
+9.0%
Q3 2014
Best reaction
-10.7%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.4% | +0.0% | +1.2% | |
| Q4 2025 | -2.7% | -1.9% | -11.7% | |
| Q3 2025 | +1.4% | +1.7% | +5.4% | |
| Q1 2025 | -1.3% | -5.4% | -7.4% | |
| Q4 2024 | +4.8% | +8.5% | +8.6% | |
| Q3 2024 | -4.9% | -5.0% | -6.7% | |
| Q2 2024 | +3.2% | +5.3% | +6.7% | |
| Q1 2024 | -10.7% | -10.8% | -18.0% | |
| Q4 2023 | +3.0% | +2.4% | -3.9% | |
| Q3 2023 | -2.2% | -6.4% | +13.5% | |
| Q2 2023 | +1.6% | +1.1% | +7.1% | |
| Q1 2023 | -3.3% | +1.5% | -7.4% | |
| Q4 2022 | -2.4% | -0.9% | -7.7% | |
| Q3 2022 | -6.3% | -5.3% | +6.0% | |
| Q2 2022 | +7.3% | +10.4% | +3.4% | |
| Q1 2022 | +4.2% | +5.1% | +2.1% | |
| Q4 2021 | -9.4% | -8.5% | -7.4% | |
| Q3 2021 | +6.5% | +11.8% | +19.3% | |
| Q2 2021 | +0.2% | -1.2% | +6.6% | |
| Q1 2021 | -3.2% | -2.6% | -3.9% | |
| Q4 2020 | -7.1% | -6.5% | -9.4% | |
| Q3 2020 | +0.5% | -0.2% | +4.2% | |
| Q2 2020 | -1.8% | -2.8% | -37.9% | |
| Q1 2020 | -2.6% | -4.4% | +12.8% | |
| Q4 2019 | -1.3% | +3.7% | -12.6% | |
| Q3 2019 | +2.5% | +6.5% | +14.8% | |
| Q2 2019 | -1.9% | -4.2% | -5.4% | |
| Q1 2019 | -0.5% | +0.0% | +4.1% | |
| Q4 2018 | -3.1% | +1.7% | -2.9% | |
| Q3 2018 | +4.9% | -0.8% | +1.0% | |
| Q2 2018 | -1.5% | +4.7% | -1.0% | |
| Q1 2018 | +1.7% | +2.9% | +14.0% | |
| Q4 2017 | -1.4% | -1.4% | -6.4% | |
| Q3 2017 | -1.9% | -3.2% | -2.5% | |
| Q2 2017 | +1.7% | +1.2% | +3.0% | |
| Q1 2017 | -1.8% | -5.0% | -5.5% | |
| Q4 2016 | -2.5% | +4.6% | -2.7% | |
| Q3 2016 | -0.8% | +1.2% | +8.9% | |
| Q2 2016 | -2.5% | -6.2% | -5.6% | |
| Q1 2016 | -3.5% | — | — | |
| Q4 2015 | +5.0% | — | — | |
| Q3 2015 | +2.9% | — | — | |
| Q2 2015 | -1.7% | — | — | |
| Q1 2015 | +0.6% | — | — | |
| Q4 2014 | +2.7% | — | — | |
| Q3 2014 | +9.0% | — | — | |
| Q2 2014 | +1.3% | — | — | |
| Q1 2014 | -0.9% | — | — | |
| Q4 2013 | +1.3% | — | — | |
| Q3 2013 | -2.1% | — | — | |
| Q2 2013 | +1.0% | — | — | |
| Q1 2013 | +1.4% | — | — | |
| Q4 2012 | +1.7% | — | — | |
| Q3 2012 | -4.7% | — | — | |
| Q2 2012 | -5.2% | — | — | |
| Q1 2012 | -1.4% | — | — | |
| Q4 2011 | -0.0% | — | — | |
| Q3 2011 | -7.2% | — | — | |
| Q2 2011 | -6.5% | — | — | |
| Q4 2010 | +3.2% | — | — | |
| Q1 2011 | +1.8% | — | — | |
| Q4 2008 | +0.3% | — | — | |
| Q3 2010 | +4.0% | — | — | |
| Q3 2009 | +4.0% | — | — | |
| Q4 2009 | -0.6% | — | — | |
| Q2 2009 | -0.6% | — | — | |
| Q2 2010 | -0.6% | — | — | |
| Q1 2010 | -8.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro